Actinium Pharmaceuticals, Inc (ATNM) is a publicly traded Healthcare sector company. As of July 27, 2026, ATNM trades at $0.87 with a market cap of $26.98M and a P/E ratio of -1.15. ATNM moved +1.16% today. Year to date, ATNM is -39.01%; over the trailing twelve months it is -52.75%. Its 52-week range spans $0.86 to $2.41. Analyst consensus is buy with an average price target of $4.00. Rallies surfaces ATNM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Actinium’s ATNM-400 Overcomes Triple-ARPI Resistance with 94% Tumor Inhibition: Actinium’s ATNM-400 achieved 94% tumor growth inhibition in ARPI-resistant prostate cancer models, outperforming apalutamide (32%) and darolutamide (5%), and matched or exceeded 177Lu-PSMA-617 efficacy. The alpha-emitter conjugate maintained a clean safety profile in single and repeat dosing, offering flexible regimens and addressing a cohort of over 100,000 mCRPC patients.
| Metric | Value |
|---|---|
| Price | $0.87 |
| Market Cap | $26.98M |
| P/E Ratio | -1.15 |
| EPS | $-0.75 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.41 |
| 52-Week Low | $0.86 |
| Volume | 127 |
| Avg Volume | 0 |
| Revenue (TTM) | $90.00K |
| Net Income | $-23.47M |
| Gross Margin | 0.00% |
1 analysts cover ATNM: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.00.